Clorox Co (CLX) Expected to Announce Quarterly Sales of $1.51 Billion

Wall Street analysts expect Clorox Co (NYSE:CLX) to report $1.51 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Clorox’s earnings. The lowest sales estimate is $1.50 billion and the highest is $1.52 billion. Clorox reported sales of $1.48 billion during the same quarter last year, which indicates a positive year over year growth rate of 2%. The company is expected to issue its next earnings report on Wednesday, May 2nd.

On average, analysts expect that Clorox will report full-year sales of $1.51 billion for the current year, with estimates ranging from $6.11 billion to $6.14 billion. For the next fiscal year, analysts expect that the business will post sales of $6.30 billion per share, with estimates ranging from $6.26 billion to $6.35 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Clorox.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Friday, February 2nd. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.01. Clorox had a net margin of 13.21% and a return on equity of 126.70%. The company had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the firm posted $1.14 earnings per share. The company’s quarterly revenue was up .7% compared to the same quarter last year.

A number of equities analysts have commented on the stock. Argus cut shares of Clorox from a “buy” rating to a “hold” rating and cut their price target for the stock from $150.40 to $127.81 in a research note on Thursday, February 8th. Zacks Investment Research raised shares of Clorox from a “hold” rating to a “buy” rating and set a $147.00 price target for the company in a research report on Tuesday, February 6th. BMO Capital Markets set a $147.00 price objective on shares of Clorox and gave the stock a “buy” rating in a report on Monday, February 5th. Bank of America decreased their price objective on shares of Clorox from $155.00 to $140.00 and set a “neutral” rating for the company in a report on Monday, February 5th. Finally, Morgan Stanley decreased their price target on shares of Clorox from $140.00 to $133.00 and set an “equal weight” rating for the company in a research note on Monday, February 5th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company’s stock. Clorox presently has a consensus rating of “Hold” and a consensus price target of $132.46.

In other news, SVP Michael R. Costello sold 10,574 shares of the company’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the transaction, the senior vice president now owns 34,867 shares in the company, valued at $4,742,260.67. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC boosted its position in Clorox by 0.8% in the 2nd quarter. FMR LLC now owns 106,828 shares of the company’s stock worth $14,234,000 after purchasing an additional 879 shares in the last quarter. Verition Fund Management LLC purchased a new position in shares of Clorox during the 2nd quarter valued at approximately $251,000. Assenagon Asset Management S.A. acquired a new position in Clorox in the 3rd quarter valued at $233,000. Fisher Asset Management LLC raised its stake in Clorox by 343.9% in the 3rd quarter. Fisher Asset Management LLC now owns 11,227 shares of the company’s stock valued at $1,481,000 after purchasing an additional 8,698 shares during the last quarter. Finally, Oakbrook Investments LLC acquired a new position in Clorox in the 3rd quarter valued at $284,000. Hedge funds and other institutional investors own 74.11% of the company’s stock.

Shares of Clorox (NYSE CLX) opened at $126.29 on Thursday. The company has a debt-to-equity ratio of 2.35, a quick ratio of 0.86 and a current ratio of 1.22. Clorox has a twelve month low of $124.09 and a twelve month high of $150.40. The firm has a market cap of $16,664.65, a P/E ratio of 23.29, a P/E/G ratio of 2.41 and a beta of 0.31.

The company also recently announced a quarterly dividend, which will be paid on Friday, May 11th. Shareholders of record on Wednesday, April 25th will be issued a $0.96 dividend. The ex-dividend date is Tuesday, April 24th. This is an increase from Clorox’s previous quarterly dividend of $0.84. This represents a $3.84 dividend on an annualized basis and a yield of 3.04%. Clorox’s payout ratio is currently 55.45%.

TRADEMARK VIOLATION WARNING: “Clorox Co (CLX) Expected to Announce Quarterly Sales of $1.51 Billion” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/clorox-co-clx-expected-to-announce-quarterly-sales-of-1-51-billion.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply